Combining AdipoRon with Paclitaxel Unveils Synergistic Potential in Non-Small Cell Lung Cancer Cells via AMPK-ERK1/2 Signaling
As part of chemotherapy regimens, Paclitaxel improves the overall survival of many non-small cell lung cancer (NSCLC) patients.However, the development of Supplement drug resistance and adverse events limits its clinical usage, reinforcing the need for further advancements in NSCLC therapeutics.We recently recognized the adiponectin receptor agonis